Determining the optimal antithrombotic regimen to prevent ischemic events and bleeding presents a challenge to cardiologists in managing their patients with atrial fibrillation (AF) who experience an acute coronary syndrome (ACS) and/or undergo percutaneous coronary intervention (PCI). The general consensus is to continue oral anticoagulation (OAC) to prevent stroke and to modify antiplatelet intensity and/or duration to minimize bleeding; however, the optimal combination has yet to be identified [1,2].
